

For my Geetu

Team Aditika for the win

INI-CET Combined MCQ Practice - All PDFs Combined

This is a pooled practice set made from the earlier drug, PSM and clinical-pearl PDFs, plus the government schemes / launches sheet.

Practice instructions

- Try answering first without looking at the answer key.
- Questions are mixed by theme but grouped section-wise for easier revision.
- Answer key with one-line explanations is given at the end.

Section A - New Drugs

Q1. Which FDA novel approval in January 2025 was approved for moderate to severe acute pain?

- A. Journavx
- B. Blujepa
- C. Qfitlia
- D. Datroway

Q2. Blujepa (gepotidacin) was approved for which indication?

- A. Acute pyelonephritis
- B. Uncomplicated urinary tract infection
- C. Complicated UTI with sepsis
- D. Gonorrhoea

Q3. Nuzolvence (zolidodacin) was approved for:

- A. Syphilis
- B. Chlamydia
- C. Uncomplicated urogenital gonorrhoea
- D. PID

Q4. Enflonsia (clesrovimab-cfor) is used for:

- A. Treatment of RSV bronchiolitis in adults
- B. Prevention of RSV LRTD in neonates and infants entering first RSV season
- C. Treatment of influenza in elderly
- D. Prevention of measles in infants

Q5. Awiqli (insulin icodec-abae) was approved to improve glycaemic control in:

- A. Type 1 diabetes only
- B. Adults with type 2 diabetes mellitus
- C. Gestational diabetes
- D. Pediatric type 2 diabetes only

Q6. Foundayo (orforglipron) is an approval related to:

- A. Acute pain
- B. Migraine prophylaxis
- C. Obesity / overweight with at least one weight-related comorbidity
- D. GERD

Q7. Lerochol (lerodalciabep-liga) is primarily a new approval for reducing:

- A. Triglycerides only
- B. LDL cholesterol
- C. Lipoprotein(a) only
- D. HDL cholesterol

Q8. Redemplo (plozasiran) was approved to reduce triglycerides in:

- A. Metabolic syndrome
- B. Familial chylomicronemia syndrome
- C. Type 2 diabetes
- D. NAFLD

Q9. Rimegepant ODT 75 mg, approved by CDSCO in 2025, is for:

- A. Acute migraine treatment
- B. Migraine prophylaxis in pregnancy
- C. Cluster headache
- D. Tension headache

Q10. Brexpiprazole tablets approved by CDSCO in 2026 are indicated for:

- A. Bipolar depression only
- B. Schizophrenia
- C. Acute delirium
- D. Narcolepsy

Q11. Tegoprazan 25 mg tablet was approved for:

- A. Acute erosive GERD
- B. Maintenance of healed erosive GERD
- C. Acute pancreatitis
- D. H. pylori eradication

Q12. Sodium zirconium cyclosilicate oral suspension was approved for treatment of:

- A. Hyponatraemia
- B. Hyperkalaemia
- C. Hypercalcaemia
- D. Metabolic acidosis

Q13. Siponimod hemifumarate was approved for:

- A. Primary progressive multiple sclerosis
- B. Secondary progressive multiple sclerosis with active disease
- C. Neuromyelitis optica
- D. Myasthenia gravis

Q14. Letermovir approval in CDSCO 2025 is linked with which area?

- A. CMV prophylaxis
- B. Influenza treatment
- C. COVID treatment
- D. Rabies prevention

Q15. Pitolisant tablets were approved for adults with narcolepsy having:

- A. Parkinsonism
- B. Excessive daytime sleepiness or cataplexy
- C. REM sleep behaviour disorder only
- D. Obstructive sleep apnoea

Q16. Lutetium Lu-177 vipivotide tetraxetan is linked with:

- A. PSMA-positive metastatic castration-resistant prostate cancer
- B. HCC
- C. Medullary thyroid carcinoma
- D. Renal cell carcinoma

Q17. Fexuprazan hydrochloride tablets 40 mg were approved for:

- A. Erosive esophagitis
- B. Ulcerative colitis
- C. Acute gastritis
- D. Peptic perforation

Q18. Which one is correctly matched?

- A. Journavx - osteoporosis
- B. Awiqli - type 2 diabetes mellitus
- C. Redemplo - LDL lowering
- D. Blujepa - gonorrhoea

Section B - PSM / Community Medicine

Q19. Population-based screening under NP-NCD is offered to which age group?

- A. All above 18 years
- B. All above 25 years
- C. All above 30 years
- D. All above 40 years

Q20. According to the 2025 NP-NCD module, annual screening is done for:

- A. HTN and DM
- B. HTN, DM and all cancers
- C. Only cervical cancer
- D. Only diabetes

Q21. Common cancers in population-based screening are screened once every:

- A. Year
- B. 2 years
- C. 3 years
- D. 5 years

Q22. NPCDCS is documented in the updated module as renamed to:

- A. NP-NCD
- B. NCDCS Plus
- C. National NCD Mission
- D. NCD Bharat

Q23. At Ayushman Arogya Mandir Sub-Centre level, the number of essential diagnostics listed is:

- A. 10
- B. 14
- C. 28
- D. 63

Q24. At Ayushman Arogya Mandir PHC level, the number of essential diagnostics listed is:

- A. 14
- B. 30
- C. 45
- D. 63

Q25. The 2nd edition of National Essential Diagnostics List (NEDL) was released in:

- A. 2022
- B. 2023
- C. 2024

D. 2025

Q26. Anaemia in pregnancy in the cited IV iron guideline is defined as Hb:

- A. < 9 g/dL
- B. < 10 g/dL
- C. < 11 g/dL
- D. < 12 g/dL

Q27. Anaemia in women of reproductive age including lactating mothers is defined as Hb:

- A. < 10 g/dL
- B. < 11 g/dL
- C. < 12 g/dL
- D. < 13 g/dL

Q28. Ferritin level suggesting iron deficiency in pregnant women in the guideline is:

- A. < 10 ug/L
- B. < 15 ug/L
- C. < 30 ug/L
- D. < 50 ug/L

Q29. Ferritin level suggesting iron deficiency in non-pregnant women is:

- A. < 15 ug/L
- B. < 20 ug/L
- C. < 30 ug/L
- D. < 40 ug/L

Q30. The 2025 IV iron guideline states that _____ remains first-line therapy.

- A. Iron sucrose
- B. Ferric carboxymaltose
- C. Oral iron
- D. Blood transfusion

Q31. Which IV iron option is specifically noted as a single-dose infusion option in pregnant and postpartum women?

- A. Iron dextran
- B. Ferric carboxymaltose
- C. Ferrous sulfate
- D. Ferritin infusion

Q32. Under the Viksit Bharat mandate, the 2029 target for both ORS and zinc coverage is:

- A. 75%
- B. 80%
- C. 90%

D. 95%

Q33. The stated ultimate goal of the STOP Diarrhoea Campaign 2025 is:

- A. Reduce dehydration by half
- B. Zero child deaths due to diarrhoea
- C. 100% stool testing
- D. Universal rotavirus vaccination only

Q34. FBNC Operational Guidelines 2025 include which concept/unit aiming for 'no separation' of mother and newborn?

- A. SNCU
- B. NBSU
- C. MNCU
- D. PICU

Q35. NAP-AMR 2.0 covers which period?

- A. 2024-2028
- B. 2025-2029
- C. 2026-2030
- D. 2025-2030

Q36. In the cited NP-NCD workflow, lipid profile is best understood as:

- A. A separate population-based screening target
- B. Part of diagnostic support / service package, not a separate named PBS target
- C. A school health intervention
- D. Only a district hospital test

Section C - Clinical Pearls

Q37. For acutely ill hospitalized patients, the 2026 SSC guidance prefers which screening approach over qSOFA alone?

- A. Only qSOFA
- B. NEWS / NEWS2 / MEWS / SIRS
- C. Only CRP
- D. Only procalcitonin

Q38. If at least two qSOFA components are positive, SCCM states the patient should be examined for:

- A. Organ failure
- B. Pulmonary embolism
- C. DIC only
- D. Stroke only

Q39. Blood cultures in suspected sepsis should be collected:

- A. Only after antibiotics
- B. As soon as possible and ideally before antibiotics
- C. Only after lactate normalizes
- D. Not routinely needed

Q40. Lactate measurement is recommended in:

- A. Every fever patient
- B. Possible / probable / definite sepsis or septic shock
- C. Only postoperative patients
- D. Only meningitis

Q41. Immediate antibiotics, ideally within 1 hour, are recommended for:

- A. Only mild sepsis
- B. Possible / probable / definite septic shock and probable / definite sepsis without shock
- C. Only culture-positive sepsis
- D. Only ICU patients after CT scan

Q42. Suggested initial fluid resuscitation in sepsis-induced hypoperfusion or septic shock is:

- A. 10 mL/kg crystalloid in 1 hour
- B. 20 mL/kg colloid in 6 hours
- C. At least 30 mL/kg IV crystalloid in first 3 hours
- D. 50 mL/kg DNS immediately

Q43. Initial MAP target in septic shock in the cited guidance is:

- A. 55 mm Hg
- B. 60 mm Hg
- C. 65 mm Hg
- D. 75 mm Hg

Q44. Sepsis should not be ruled in or ruled out by:

- A. Clinical judgement
- B. A single biomarker or diagnostic test
- C. Repeated assessment
- D. Source evaluation

Q45. Current exam pearl regarding qSOFA is:

- A. It is the preferred sole in-hospital screening tool
- B. It is useless and should be forgotten
- C. It still matters as bedside prompt / prognostic alert but is not preferred as sole screening tool
- D. It replaces lactate

Q46. In Indian NP-NCD public-health workflow, lipids are best remembered as:

- A. A named population-based screening target
- B. A diagnostic service rather than a separate named PBS target
- C. A school-based screening mandate
- D. An immunization item

Q47. Which of the following is correctly matched for lipid-related new approvals?

- A. Lerochol - triglyceride lowering in FCS
- B. Redemplo - LDL lowering
- C. Lerochol - LDL lowering
- D. Awiqli - LDL lowering

Q48. Redemplo is most closely linked with reduction of:

- A. LDL only
- B. Triglycerides in familial chylomicronemia syndrome
- C. HbA1c
- D. Uric acid

Q49. Awiqli is best remembered in revision as:

- A. Once-weekly basal insulin
- B. Daily premixed insulin
- C. Oral GLP-1 drug
- D. Rapid-acting insulin analogue

Q50. Enflonsia is most relevant to which preventive area?

- A. HPV prevention
- B. RSV prevention in infants entering first season
- C. Influenza prophylaxis in adults
- D. TB chemoprophylaxis

Q51. Blujepa is a high-yield infectious disease approval for:

- A. Uncomplicated UTI
- B. Gonorrhoea
- C. Acute bronchitis
- D. Typhoid

Q52. Nuzolvence is a high-yield infectious disease approval for:

- A. Uncomplicated urogenital gonorrhoea
- B. Malaria
- C. Kala-azar
- D. Meningococcal disease

Q53. Which one is the best exam statement?

- A. qSOFA has replaced all bedside tools.
- B. A single biomarker is enough to diagnose sepsis.
- C. Sepsis is a clinical diagnosis and should not be ruled in / out by a single test.
- D. Lactate is no longer recommended.

Q54. Initial vasopressor resuscitation target to remember for septic shock is:

- A. MAP 50
- B. MAP 55
- C. MAP 65
- D. MAP 80

Section D - Government Schemes / Launches

Q55. Delhi became which State/UT to implement AB PM-JAY in April 2025?

- A. 33rd
- B. 34th
- C. 35th
- D. 36th

Q56. Card distribution in Delhi for the scheme was stated to start from:

- A. 05 Apr 2025
- B. 10 Apr 2025
- C. 14 Apr 2025
- D. 01 May 2025

Q57. The Delhi government announced what additional top-up over the central AB PM-JAY cover?

- A. Rs. 1 lakh
- B. Rs. 2 lakh
- C. Rs. 3 lakh
- D. Rs. 5 lakh

Q58. Ayushman Vay Vandana Yojana covers senior citizens aged:

- A. 60 years and above
- B. 65 years and above
- C. 70 years and above
- D. 75 years and above

Q59. Under AVVY, eligible senior citizens are covered irrespective of:

- A. Blood group
- B. Socio-economic status
- C. State of residence

D. Hospital type

Q60. Pre-existing diseases under AVVY are covered from:

- A. Day one
- B. After 30 days
- C. After 6 months
- D. After 1 year

Q61. Swasth Nari, Sashakt Parivar Abhiyaan ran from:

- A. 01 Sep to 15 Sep 2025
- B. 17 Sep to 02 Oct 2025
- C. 02 Oct to 17 Oct 2025
- D. 01 Nov to 15 Nov 2025

Q62. More than how many health camps were planned under the SNSP Abhiyaan?

- A. 1 lakh
- B. 5 lakh
- C. 10 lakh
- D. 20 lakh

Q63. SNSP Abhiyaan was jointly led by MoHFW and which other ministry?

- A. Ministry of Education
- B. Ministry of Women & Child Development
- C. Ministry of Rural Development
- D. Ministry of Social Justice

Q64. SAHI stands for:

- A. Secure AI for Health India
- B. Strategy for Artificial Intelligence in Healthcare for India
- C. System for AI Health Integration
- D. Smart AI Health Interface

Q65. BODH stands for:

- A. Benchmarking Open Data Platform for Health AI
- B. Bioinformatics Open Database for Health
- C. Better Outcomes Data Hub
- D. Base Open Digital Health

Q66. The nationwide HPV Vaccination Programme was launched on:

- A. 17 Feb 2026
- B. 28 Feb 2026
- C. 17 Mar 2026

D. 24 Mar 2026

Q67. The nationwide HPV programme targets approximately how many girls aged 14 years every year?

- A. 15 lakh
- B. 50 lakh
- C. 1.15 crore
- D. 2.5 crore

Q68. The HPV vaccine in the national campaign is to be provided:

- A. Only in private hospitals
- B. Free of cost at designated government health facilities
- C. Only through schools
- D. Only after payment through PM-JAY

Q69. The HPV campaign initially runs in mission mode for:

- A. 2 weeks
- B. 1 month
- C. 3 months
- D. 6 months

Q70. HPV vaccination under the programme is:

- A. Compulsory without consent
- B. Voluntary with informed parent / guardian consent
- C. Only for school-going girls
- D. Only for urban girls

Q71. The intensified 100-Day TB Mukh Bharat campaign launched in March 2026 covers:

- A. 15,800 villages
- B. 1.58 lakh villages and urban wards
- C. Only metropolitan cities
- D. Only aspirational districts

Q72. The AI-enabled multilingual chatbot on the TB Mukh Bharat App is called:

- A. Asha
- B. Khushi
- C. Jeevan
- D. Swasthya

Q73. NAP-AMR 2.0 was launched in:

- A. Jan 2025
- B. Jun 2025
- C. Nov 2025

D. Jan 2026

Q74. As on 30 Nov 2025, the number of operational Ayushman Arogya Mandirs reported in the official achievement note was:

- A. 1,50,000
- B. 1,81,873
- C. 1,95,000
- D. 2,10,000

Q75. Ayushman Arogya Mandirs were noted as having an expanded package of:

- A. 8 services
- B. 10 services
- C. 12 services
- D. 15 services

Q76. Which one is correctly matched?

- A. SAHI - TB tracking app
- B. BODH - Benchmarking Open Data Platform for Health AI
- C. AVVY - programme only for BPL above 80 years
- D. SNSP - exclusive hospital insurance scheme

Answer key

Section A - New Drugs

Q	Ans	One-line explanation
1	A	Journavx is the brand name for suzetrigine, approved for moderate to severe acute pain.
2	B	Blujepa (gepotidacin) is a high-yield 2025 FDA approval for uncomplicated UTI.
3	C	Nuzolvence (zoliflodacin) is the 2025 FDA approval for uncomplicated urogenital gonorrhoea.
4	B	Enflonsia is a prevention approval for RSV lower respiratory tract disease in neonates and infants entering the first RSV season.
5	B	Awikli is the once-weekly basal insulin approval for adults with type 2 diabetes mellitus.
6	C	Foundayo (orforglipron) was approved for weight reduction in adults with obesity or overweight plus a weight-related comorbidity.
7	B	Lerochol is the LDL-lowering approval, including heterozygous familial hypercholesterolaemia.
8	B	Redemplo (plozasiran) is the 2025 FDA approval for triglyceride reduction in familial chylomicronemia syndrome.
9	A	CDSCO approved rimegepant ODT 75 mg for acute treatment of migraine in adults with prior insufficient response to triptans.
10	B	Brexpiprazole is a high-yield CDSCO 2026 approval for treatment of schizophrenia.
11	B	Tegoprazan 25 mg is the maintenance-strength approval for healed erosive GERD.
12	B	Sodium zirconium cyclosilicate is a potassium-lowering drug approved for hyperkalaemia.
Q	Ans	One-line explanation
13	B	Siponimod is the CDSCO-approved agent for active SPMS.
14	A	Letermovir is high-yield for CMV prophylaxis in adult CMV-seropositive allogeneic HSCT recipients and selected kidney transplant recipients.
15	B	Pitolisant is a wake-promoting approval for narcolepsy with excessive daytime sleepiness or cataplexy.
16	A	Lu-177 vipivotide tetraxetan is the PSMA-targeted radioligand therapy approval for metastatic CRPC.
17	A	Fexuprazan is a P-CAB-type acid suppression approval for erosive esophagitis.
18	B	Awikli = insulin icodec-abae = approval for adults with type 2 diabetes mellitus.

Section B - PSM / Community Medicine

Q	Ans	One-line explanation
19	C	The NP-NCD module states population-based screening is offered to all individuals aged 30 years and above.
20	A	In the cited module, hypertension and diabetes are screened yearly.
21	D	Oral, breast and cervical cancers are noted as once-in-five-years screening targets.
22	A	The programme name change to NP-NCD is documented in the 2025 module.
23	B	AAM Sub-Centre level is mapped to 14 essential diagnostics.
24	D	AAM PHC level is mapped to 63 essential diagnostics.
25	D	ICMR released the 2nd edition of NEDL in 2025.
26	C	Pregnancy threshold used in the guideline is Hb < 11 g/dL.
27	C	For women of reproductive age including lactating mothers, the threshold is Hb < 12 g/dL.
28	C	Pregnant women: ferritin < 30 ug/L.
29	A	Non-pregnant women: ferritin < 15 ug/L.
30	C	The guideline clearly keeps oral iron as first-line therapy.
Q	Ans	One-line explanation
31	B	Ferric carboxymaltose is highlighted as a single-dose infusion option.
32	C	The STOP Diarrhoea Campaign 2025 document fixes ORS and zinc coverage targets at 90% by 2029.
33	B	The document explicitly states the ultimate goal is zero child deaths due to diarrhoea.
34	C	MNCU = Mother Newborn Care Unit, linked with the 'no separation' concept.
35	B	NAP-AMR 2.0 is officially for 2025-2029.
36	B	The module includes lipid profile in diagnostic service packages, but not as a stand-alone named PBS target.

Section C - Clinical Pearls

Q	Ans	One-line explanation
37	B	SSC 2026 prefers NEWS, NEWS2, MEWS or SIRS rather than qSOFA as the sole screening tool.
38	A	qSOFA ≥ 2 is a bedside alert prompting examination for organ failure.
39	B	SSC 2026 recommends blood cultures as soon as possible and ideally before antibiotics.
40	B	The 2026 guidance emphasizes lactate in possible, probable or definite sepsis and in septic shock.
41	B	That is the high-yield timing emphasis from SSC 2026.
42	C	The suggested starting point remains at least 30 mL/kg crystalloid in the first 3 hours.
43	C	Initial MAP target: 65 mm Hg.
44	B	SSC 2026 explicitly states sepsis remains a clinical diagnosis and should not hinge on one test.
45	C	That is the nuanced modern exam answer.
46	B	For MCQ purposes, lipids are in diagnostic services, not listed as a stand-alone PBS target in the cited NP-NCD module.
47	C	Lerochol = LDL lowering; Redemplo = triglycerides in familial chylomicronemia syndrome.
48	B	Redemplo = plozasiran = triglyceride reduction in FCS.

Q	Ans	One-line explanation
49	A	Awikli is the once-weekly basal insulin approval.
50	B	Enflonsia is the RSV prevention approval for neonates and infants entering the first RSV season.
51	A	Blujepa = gepotidacin = uncomplicated UTI.
52	A	Nuzolvence = zoliflodacin = uncomplicated urogenital gonorrhoea.
53	C	That is the exact style of current high-yield SSC 2026 exam pearl.
54	C	MAP 65 mm Hg is the standard initial target in the cited guidance.

Section D - Government Schemes / Launches

Q	Ans	One-line explanation
55	C	Delhi became the 35th State/UT to implement AB PM-JAY.

Q	Ans	One-line explanation
56	B	The official release said card distribution would be initiated from 10 Apr 2025.
57	D	The Delhi top-up mentioned was an additional Rs. 5 lakh.
58	C	AVVY is the 70 years and above extension.
59	B	The release specifically says irrespective of socio-economic status.
60	A	Pre-existing diseases were stated to be covered from day one.
61	B	The campaign window was 17 Sep 2025 to 02 Oct 2025.
62	C	Officially, more than 10 lakh health camps were planned.
63	B	It was jointly led by MoHFW and MoWCD.
64	B	SAHI = Strategy for Artificial Intelligence in Healthcare for India.
65	A	BODH = Benchmarking Open Data Platform for Health AI.
66	B	The national HPV campaign launch date was 28 Feb 2026.

Q	Ans	One-line explanation
67	C	The programme targets approximately 1.15 crore girls aged 14 years every year.
68	B	The vaccine was stated to be free of cost at designated government health facilities.
69	C	The special mission-mode campaign was stated to run for 3 months.
70	B	The release states vaccination is voluntary with informed consent from parents/guardians.
71	B	Coverage stated: 1.58 lakh villages and urban wards.
72	B	The release identifies 'Khushi' as the AI-enabled multilingual chatbot.
73	C	NAP-AMR 2.0 was launched on 18 Nov 2025.
74	B	The official achievement snapshot gives 1,81,873 operational AAMs as on 30 Nov 2025.
75	C	The cited achievement note states an expanded package of 12 services.
76	B	BODH is correctly expanded as Benchmarking Open Data Platform for Health AI.

Final revision strip

- Journavx = acute pain; Blujepa = uncomplicated UTI; Nuzolvence = gonorrhoea; Enflonsia = RSV prevention.
- Awikli = once-weekly basal insulin for T2DM; Foundayo = obesity / overweight with comorbidity.
- NP-NCD PBS age = 30+; yearly HTN + DM; every 5 years = oral + breast + cervical cancer.
- SSC 2026: NEWS / NEWS2 / MEWS / SIRS preferred over qSOFA alone; fluids 30 mL/kg; MAP 65.
- Delhi 35th State/UT under AB PM-JAY in Apr 2025; SNSP = 17 Sep to 02 Oct 2025; HPV campaign = 28 Feb 2026; TB 100-day campaign = 24 Mar 2026.

Official sources used

Source	URL
FDA novel drug approvals 2025	https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
FDA novel drug approvals 2026	https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
CDSCO approved new drugs index	https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/
CDSCO 2026 new drugs PDF	https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/List%20of%20New%20Drugs%20approved%20in%20the%20year%202026%20till%20date.pdf
CDSCO 2025 accessible new drugs PDF snapshot	https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/List%20of%20New%20Drugs%20approved%20in%20the%20year%2020251sep25.pdf
NHM Medical Officer training module for NP-NCD	https://nhm.gov.in/New-Update-2025-26/Whats-new/NCD-Medical-Officers.pdf
ICMR National Essential Diagnostics List 2025, 2nd edition	https://www.icmr.gov.in/icmrobject/uploads/Report/1752588650_nedl2ndedition.pdf
NHM guideline: IV iron in pregnant and lactating women	https://nhm.gov.in/images/pdf/Nutrition/AMB-guidelines/Operational%20Guidelines%20for%20use%20use%20of%20Intravenous%20Iron%20in%20Pregnant%20and%20Lactating%20Women.pdf
NHM STOP Diarrhoea Campaign 2025 guidance	https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCHA/CH/Schemes/IDCF/IDCF-2025/Guidance_Document_on-STOP_Diarrhoea_Campaign_2025.pdf
NHM FBNC 2025 PDF	https://nhm.gov.in/images/pdf/programmes/CH-Programmes/FBNC/FBNC%20Operational%20Guidelines%202025.pdf
SCCM sepsis definitions	https://www.sccm.org/clinical-resources/sepsis-definitions
SCCM Surviving Sepsis Campaign 2026	https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-septic-shock-2026

Source	URL
Delhi becomes 35th State/UT to implement AB PM-JAY	https://www.pib.gov.in/PressReleaseDetailm.aspx?PRID=2119281
Swasth Nari, Sashakt Parivar Abhiyaan launch	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2167698
NAP-AMR 2.0 launch	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2191165
Initiatives & Achievements-2025	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2210432
SAHI and BODH launch	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2229226
Nationwide HPV vaccination programme launch	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233632
Intensified 100-Day TB Mukht Bharat Campaign	https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244703